This study establishes MPXV clade IIb-infected SCID mouse models presenting with pneumonia, lesions, and localized inflammation that recapitulate key clinical manifestations observed in high-risk populations, and demonstrates that the timing of treatment initiation and the stage of disease progression critically influence the anti-MPXV efficacy of both tecovirimat and cidofovir.
- Xinyu Cao
- Ning Shi
- Huijun Lu